Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308

Journal of Medicinal Chemistry

Volumn 42, Issue 25, 1999, Pages 5254-5265

  Hoekstra, William J ^a   Maryanoff, Bruce E ^a   Damiano, Bruce P ^a   Andrade Gordon, Patricia ^a   Cohen, Judith H ^a   Costanzo, Michael J ^a   Haertlein, Barbara J ^a   Hecker, Leonard R ^a   Hulshizer, Becky L ^a   Kauffman, Jack A ^a   Keane, Patricia ^a   McComsey, David F ^a   Mitchell, John A ^a   Scott, Lorraine ^a   Shah, Rekha D ^a   Yabut, Stephen C ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [3 (4 PIPERIDINYL)PROPIONYL]NIPECOTOYLAMINO] 3 (3 PYRIDYL)PROPIONIC ACID; 3 [1 [3 (4 PIPERIDINYL)PROPIONYL]NIPECOTOYLAMINO]PROPIONIC ACID; FERRIC CHLORIDE; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TRANSFORMATION; GUINEA PIG; NONHUMAN; PHOTOACTIVATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOGS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; NIPECOTIC ACIDS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROLINE; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033576619     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990418b     Document Type: Article

References (43)

1. Phillips, D. R.; Charo, I. F.; Panse, L. V.; Fitzgerald, L. A. The Platelet Membrane Glycoprotein IIb/IIIa Complex. Blood 1988, 71, 831-843.
2. For recent reviews, see: (a) Hoekstra, W. J.; Poulter, B. L. Combinatorial Chemistry Techniques Applied to Nonpeptide Integrin Antagonists. Curr. Med. Chem. 1998, 5, 195-204.
3. (b) Coller, B. S. Platelet GPIIb/IIIa Antagonists: The First Anti-Integrin Receptor Therapeutics. J. Clin. Invest. 1997, 99, 1467-1471.
4. (c) Tcheng, J. E. Platelet Glycoprotein IIb/IIIa Integrin Blockade. Recent Clinical Trials in Interventional Cardiology. Thromb. Haemostasis 1997, 78, 205-209.
5. (d) Mousa, S. A.; Bennett, J. S. Platelets in Health and Disease: Platelet GPIIb/ IIIa Structure and Function: Recent Advances in Antiplatelet Therapy. Drugs Future 1996, 21, 1141-1154.
6. (e) Samanen, J. GPIIb/IIIa Antagonists. Annu. Rep. Med. Chem. 1996, 31, 91-100.
7. (f) Zablocki, J. A.; Rao, S. N.; Baron, D. A.; Flynn, D. L.; Nicholson, N. S.; Feigen, L. P. Fibrinogen Receptor Antagonists. Curr. Pharm. Des. 1995, 1, 533-558.
8. (a) Lincoff, A. M. Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin During Percutaneous Coronary Revascularization. N. Engl. J. Med. 1997, 336, 1689-1696.
9. (b) Califf, R. M. Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. N. Engl. J. Med. 1994, 330, 956-961.
10. (a) Scarborough, R. M. Eptifibatide. Drugs Future 1998, 23, 585-590.
11. (b) Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Design of Potent and Specific Integrin Antagonists. J. Biol. Chem. 1993, 268, 1066-1073.
12. (a) Kereiakes, D. J.; Kleiman, N. S.; Ambrose, J.; Cohen, M.; Rodriguez, S.; Palabrica, T.; Hermann, H. C.; Sutton, J. M.; Weaver, W. D. Randomized, Double-Blind Placebo-Controlled Dose-Ranging Study of Tirofiban (MK-383) Platelet IIb/IIIa Blockade in High Risk Patients Undergoing Coronary Angioplasty. J. Am. Coll. Card. 1996, 27, 536-542.
13. (b) Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
14. (a) Sheppard, L. P. Xemilofiban. IDrugs 1998, 1, 257-263.
15. (b) Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzmann, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; McMackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. J. Med. Chem. 1995, 38, 2378-2394.
16. Cannon, C. P.; McCabe, C. H.; Borzak, S.; Henry, T. D.; Tischler, M. D.; Mueller, H. S.; Feldman, R.; Palmeri, S. T.; Ault, K.; Hamilton, S. A.; Rothman, J. M.; Novotny, W. F.; Braunwald, E. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients after an Acute Coronary Syndrome. Circulation 1998, 97, 340-349.
17. (b) Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Hurzeler, M.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996, 39, 3139-3147.
18. Farrell, D. H.; Thiagarajan, P.; Chung, D. W.; Davie, E. W. Role of Fibrinogen a and y Chain Sites in Platelet Aggregation. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10729-10732.
19. Hoekstra, W. J.; Press, J. B.; Bonner, M. P.; Andrade-Gordon, P.; Keane, P. M.; Durkin, K. A.; Liotta, D. C. Adamantane and Nipecotic Acid Derivatives as Novel β-Turn Mimics. Bioorg. Med. Chem. Lett. 1994, 4, 1361-1364.
20. Fan, F.; Mayo, K. H. Effect of pH on the Conformation and Backbone Dynamics of a 27-Residue Peptide in Trifluoroethanol. J. Biol. Chem. 1995, 270, 24693-24701.
21. Mayo, K. H.; Fan, F.; Beavers, M. P.; Eckardt, A.; Keane, P.; Hoekstra, W. J.; Andrade-Gordon, P. RGD Induces Conformational Transition in Purified Platelet Integrin GPIIb/IIIa-SDS System Yielding Multiple Binding States for Fibrinogen γ-Chain C-Terminal Peptide. FEBS Lett. 1996, 378, 79-82.
22. Mayo, K. H.; Fan, F.; Beavers, M. P.; Eckardt, A.; Keane, P.; Hoekstra, W. J.; Andrade-Gordon, P. Integrin Receptor GPIIb/ IIIa Bound State Conformation of the Fibrinogen γ-Chain C-Terminal Peptide 400-411: NMR and Transfer NOE Studies. Biochemistry 1996, 35, 4434-4444.
23. Mayo, K. H.; Fan, F.; Beavers, M. P.; Eckardt, A.; Keane, P.; Hoekstra, W. J.; Andrade-Gordon, P. NOE-Derived Conformation of GRGDSP Cell Adhesion Recognition Site in the Presence of SDS Micelles and Integrin Receptor GPIIb/IIIa. Biochim. Biophys. Acta 1996, 1296, 95-102.
24. Hoekstra, W. J.; Beavers, M. P.; Andrade-Gordon, P.; Evangelisto, M. F.; Keane, P. M.; Press: J. B.; Tomko, K. A.; Fan, F.; Kloczewiak, M.; Mayo, K. H.; Durkin, K. A.; Liotta, D. C. Design and Evaluation of Nonpeptide Fibrinogen γ-Chain Based GPIIb/ IIIa Antagonists. J. Med. Chem. 1995, 38, 1582-1592.
25. For a preliminary report, see Hoekstra, W. J.; Maryanoff, B. E.; Andrade-Gordon, P.; Cohen, J. H.; Costanzo, M. J.; Damiano, B. P.; Haertlein, B. J.; Harris, B. D.; Kauffman, J. A.; Keane, P. M.; McComsey, D. F.; Villani, F. J.; Yabut, S. C. Solid-Phase Parallel Synthesis Applied to Lead Optimization: Discovery of Potent Analogues of the GPIIb/IIIa Antagonist RWJ-50042. Bioorg. Med. Chem. Lett. 1996, 6, 2371-2376.
26. (a) Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gallop, M. A. Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions. J. Med. Chem. 1994, 37, 1385-1401.
27. (b) Thompson, L. A.; Ellman, J. A. Synthesis and Applications of Small Molecule Libraries. Chem. Rev. 1996, 96, 555-600.
28. DeWitt, S. H.; Kiely, J. S.; Stankovic, C. J.; Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R. "Diversomers": An Approach to Nonpeptide, Nonoligomeric Chemical Diversity. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6909-6913.
29. Johnson, T. B.; Livak, J. E. The Synthesis of Aryl Substituted Dihydrouracils and Their Conversion to Uracil Derivatives. J. Am. Chem. Soc. 1936, 58, 299.
30. Rico, J. G.; Lindmark, R. J.; Rogers, T. E.; Bovy, P. R. A Highly Stereoselective Michael Addition to an α,β-Unsaturated Ester as the Crucial Step in the Synthesis of a Novel β-Amino Acid-Containing Fibrinogen Receptor Antagonist. J. Org. Chem. 1993, 58, 7948-7951.
31. Soloshonok, V. A.; Fokina, N. A.; Rybakova, A. V.; Shishkina, I. P.; Galushko, S. V.; Sorochinsky, A. E.; Kukhar, V. P.; Savchenko, M. V.; Svedas, V. K. Biocatalytic Approach to Enantiomerically Pure β-Amino Acids. Tetrahedron: Asymmetry 1995, 6, 1601-1610.
32. Backes, B. J.; Ellman, J. A. Carbon-Carbon Bond-Forming Methods on Solid Support. Utilization of Kenner's Safety Catch Linker. J. Am. Chem. Soc. 1994, 116, 11171-11172.
33. Hoekstra, W. J.; Greco, M. N.; Yabut, S. C.; Hulshizer, B. L.; Maryanoff, B. E. Solid-Phase Synthesis via N-Terminal Attachment to the 2-Chlorotrityl Resin. Tetrahedron Lett. 1997, 38, 2629-2632.
34. Suzuki, A. Organoboron Compounds in New Synthetic Reactions. Pure Appl. Chem. 1985, 57, 1749-1758.
35. Scott, M. K.; Jacoby, H. I.; Mills, J. E.; Bonfilio, A. C.; Rasmussen, C. R. 4-(Diphenylmethyl)-1-[(imino)methyl]piperidines as Gastric Antisecretory Agents. J. Med. Chem. 1983, 26, 535-538.
36. Aebischer, B.; Frey, P.; Haerter, H.; Herrling, P. L.; Mueller, W.; Olverman, H. J.; Watkins, J. C. Synthesis and NMDA Antagonist Properties of the Enantiomers of CCP and of the Unsaturated Analogue CCP-ene. Helv. Chim. Acta 1989, 72, 1043-1051.
37. Saunders, J.; MacLeod, A. M.; Merchant, K.; Showell, G. A.; Snow, R. J.; Street, L. J.; Baker, R. Ester Bio-isosteres: Synthesis of Oxadiazolyl-1-azabicyclo[2.2.1]heptanes as Muscarinic Agonists. J. Chem. Soc. Chem. Commun. 1988, 1618-1619.
38. Damiano, B. P.; Mitchell, J.; Giardino, E.; Corcoran, T.; Haertlein, B.; de Garavilla, L.; Kauffman, J.; Hoekstra, W. J.; Andrade-Gordon, P. The Pharmacology of RWJ-53308, a Novel Orally Active Fibrinogen Receptor Antagonist. Submitted for publication in J. Cardiovasc. Pharmacol.
39. Duggan, M. E.; Naylor-Olsen, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartman, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. J. Med. Chem. 1995, 38, 3332-3341.
40. Mousa, S. A.; Wityak, J. Orally Active Isoxazoline GPIIb/IIIa Antagonists. Cardiovasc. Drug Rev. 1998, 16, 48-61.
41. Harrington, R. A.; Graffagnino, C.; Armstrong, P. W.; Joseph, D.; Card, T. L.; Sigmon, K. N.; Granett, J. R.; Chan, R.; Califf, R.; Topol, E. J. Dose-Finding and Tolerability of a New Oral Platelet Glycoprotein IIb/IIIa Inhibitor, SB 214857, in Patients with Coronary Artery and Cerebrovascular Disease: the APLAUD Results. Circulation 1998, 98 (17), 1-251, abstract 1303.
42. (b) Carroll, R. C. Lotrafiban. Curr. Opin. Cardiovasc., Pulm. Renal Invest. Drugs 1999, 1 (1), 131-135.
43. Fujisawa Pharmaceutical Company, Ltd. has filed a patent application on structurally related GPIIb/IIIa antagonists: Ohkubo, M.; Takahashi, F.; Yamanaka, T.; Sakai, H.; Kato, M. WO 95/08536.